Links


www.hipectreatment.com

http://surgicaloncology.com 
Dr. Paul Sugerbaker- a comprehensive website with data and protcolos.

National Cancer Institute

http://en.wikipedia.org/wiki/Intraperitoneal_hyperthermic_chemoperfusion

http://www.appendix-cancer.com/oldsite/Peritoneal%20Chemotherapy%20and%20Intraoperative%20Peritoneal%20Hyperthermic%20Chemotherapy.htm


1. Esquivel J. Cytoreductive surgery for peritoneal malignancies--development of standards of care for the community. Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x.
2. Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008 Feb 28;14(8):1159-66.
3. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of IL-2 and lymphokine-activated killer cells. Surgery 1987; 102:71-78.
4. Averbach AM, Jacquet P, Sugarbaker PH. Surgical technique and colorectal cancer: impact on local recurrence and survival. Tumori 1995; 81:65-71.
5.Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996;82:79-100.
 6.Yonemura Y. Hyperthermo-chemotherapy for the treatment of peritoneal dissemination. In: Yonemoura Y, editor. Contemporary approaches toward cure of gastric cancer. Kanazawa:Maeda Shoten, 1996: 105-116.
7. Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006 Aug;32(6):602-6.
8. Tsujimoto H, Hagiwara A, Shimotsuma M, Sakakura C, Osaki K, Sasaki S, Ohyama T, Ohgaki M, Imanishi T, Yamazaki J, Takahashi T. Role of milky spots as selective implantation sites for malignant cells in peritoneal dissemination in mice. J Cancer Res Clin Oncol. 1996;122(10):590-5.
9. Tsujimoto H, Takhashi T, Hagiwara A, Shimotsuma M, Sakakura C, Osaki K, Sasaki S, Shirasu M, Sakakibara T, Ohyama T, et al. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells. Br J Cancer. 1995 Mar;71(3):468-72.
10. Shimotsuma M, Shields JW, Simpson-Morgan MW, Sakuyama A, Shirasu M, Hagiwara A, Takahashi T. Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology. 1993 Jun;26(2):90-101. Review.
 11. Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, Sakakura C, Tsujimoto H, Osaki K, Sasaki S, et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993 Feb 1;53(3):687-92.
12. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22:465- 472.
13. Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008 Sep 15;98(4):268-72.
14. Deraco M, Baratti D, Zaffaroni N, Cabras AD, Kusamura S. Advances in clinical research and management of diffuse peritoneal mesothelioma. Recent Results Cancer Res. 2007;169:137-55.
15. Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, Bloss LP, DiSaia PJ. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 1993 Sep;50(3):347- 51.
16. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1990 Jan;75(1):89-95.
17. Parkin DM, Bray F, Feraly JPP: Global cancer statistics. Ca Cancer J Clin 2005;55: 74- 108.
18. Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008 Sep 15;98(4):263-7.
19. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007 Oct;14(10):2702-13.
20. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol. 2006 Dec;33(6 Suppl 11):S10-3.
21. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidencebased approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg. 2003 Jun;196(6):954-64.
23. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008 Sep 15;98(4):283-90.
24. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ,Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.
25. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995 Jan;221(1):29-42.
26. González-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol. 2008 Sep 15;98(4):237-41.
27. Loggie BW, Fleming RA, McQuellon RP, Russel GB, Geisinger KR. Cytoreductive surgery with intraperitoneal chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66(6): 561-568.
28. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Current status and future directions. Ann Surg Oncol 2005; 12(10):756- 777. 29. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5- fluorouracil administrated intraperitoneally. Cancer Res 1980; 40:567-72.
30. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 1985; 248: F413-F424.
31. Dedrick RL. Theoretical and experimental basis of intraperitoneal chemotherapy. Semin Oncol 1985; 12 (3 Suppl 4): 1-6.
32. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986; 75: 1047- 52.
33. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-flourourcil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994; 46:685-9.
34. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89: 480-487.
35. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002; 13(2):267-72.
36. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004; 15(10):1558-65.
37. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006; 57(5):703-8.
38. Sugarbaker PH, Graves T, DeBruijn EA, et al: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990; 50:5790-5794.
39. Katz M, Barone R: The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 2003; 12:673-688.
40. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256-60.
41. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res. 1981;41(3):1096-9.
42. El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004; 6(2):117-27.
43. VanderWaal R, Thampy G, Wright WD, Roti Roti JL. Heat-induced modifications in the association of specific proteins with the nuclear matrix. Radiat Res. 1996; 145(6):746-53.
44. Roti Roti JL, Kampinga HH, Malyapa RS, et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones. 1998; 3(4):245-55.
45. Pelz JO, Doerfer J, Hohenberger W, Meyer T. A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 2005; 5(1):56
46. van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Heat penetration in locally applied hyperthermia in the abdomen during intra-postoperative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003, 23:1501-8.
47. Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987; 19:1–5.
48. Los G, Mutsaers PH, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49:3380–4.
49. Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. In Sugarbaker PH (ed.): Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic Press 1996; 155–162.
50. YanTD, Black D, Savady R, Sugarbaker PH. Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma. J Clin Oncol 2006, 24:4011-4019.
51. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42–43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A 1975; 72:937–40.
52. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis- dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980; 40:1165– 8. CRC
53. Chu DZ, Lang NP, Thompson C, et al: Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989; 63(2):364-367.
54. Jayne DG, Fook S, Loi C, et al: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89:1545-1550.
55. Sadeghi B, Arvieux C, Glehen O, et al: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:58-63. 56. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg. 1994; 94(4): 191-7.
57. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13):905-14.
58. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355(9209): 1041-7.
59. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18(1): 136-47.
60. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003; 21(11): 2059-69.
61. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22(1):23-30.
62. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2):229-37.
63. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42.
64. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23(22):4866-75.
65. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.J Clin Oncol. 2006; 24(21):3347-53.
66. Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007 Nov 20;25(33):5225-32.
67. Willet CG, Tepper JE, Cohen AM, et al: Failure patterns following curative resection of colonic carcinoma. Surgery 1984; 200:685-690.
68. Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
69. Fujimura T, Yonemura Y, Fujita H, et al: Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intraabdominal malignancies. Int Surg 1999; 84:60-66.
70. Cavaliere F, Perri P, Di Filippo F, et al: Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000; 74:41-44.
71. Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43:1341-1346.
72. Beaujard AC, Glehen O, Caillot JL, et al: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000; 88:2512-2519.
73. Culliford A, Brooks AD, Sharma S, et al: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8: 787-795.
74. Elias D, Blot F, El Otmany A, et al: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76. 75. Witkamp AJ, de Bree E, Kaag MM, et al: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37:979-984.
76. Cavaliere F, Perri P, Rossi CR, et al: Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: Experience of the Italian Society of Locoregional Integrated Therapy in Oncology. Tumori 2003; 89:21-23.
77. Pilati P, Mocellin S, Rossi CR, et al: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003; 10:508-513.
78. Shen P, Levine EA, Hall J, et al: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138:26-33.
79. Elias D, Pocard M: Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12:543-559.
80. Glehen O, Mithieux F, Osinsky D, et al: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003; 21:799-806.
81. Verwaal V, Ruth S, Bree E, et al: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737-3743.
82. Glehen O, Cotte E, Schreiber V, et al: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91:747-754.
83. Pilati P, Mocellin S, Rossi CR, et al: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003; 10:508-513.
84. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G; Society of SurgicalOncology Annual Meeting. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007 Jan;14(1):128-33.
85. Crew KD, Neugut AL. Epidemiology of Gastric Cancer. World J Gastroenterol 2006. Jan, 12(3): 354-62
86. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003 Sep;90(9):1113-9.
87. Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, Sugimachi K.Recurrences and related characteristics of gastric cancer. Br J Cancer. 1996 Sep;74(6):975-9.
88.Kodera Y, Yamamura Y, Shimizu Y et al. Peritoneal washing cytology: prognostic value of positive findings in patient with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-64
89. Sugarbaker PH, Cunliffe WJ, Belliveau J et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989; 16(4 suppl 6): 83-97
90. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitzu Y et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-62
91Cheng-Wun WU, Su-Shun Lo, King-Han Shen et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surs 1003; 327: 153-58
92. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 12: 347-53, 2005
93. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-64.
94. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.
95. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
96. Cervantes A, Roselló S, Roda D, Rodríguez-Braun E. The treatment of advanced gastric cancer: current strategies and future perspectives.Ann Oncol. 2008 Jul;19 Suppl 5:v103-7. Ovary
97. Olivier RI, Lubsen-Brandsma MAC, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gyn Onc 2006; 100(1):20-26.
98. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K et al. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. NEJM 1996; 334(1):1-6.
99. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
100. Albers DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. NEJM 1996; 335:1950-1955.
101. Markman M, Bundy B, Albers DS, Fowler JM, Clark-Pearson DL, Carson LF et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately highdose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwesters oncology group, and eastern cooperative oncology group. J Clin Oncology 2001; 19:1001-1007.
102. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD,Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000 Jan;18(1):106-15.
103. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute monograph 1975; 42:101-104.
104. Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz FJ. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta- Analysis. Journal of Clinical Oncology 2002; 20(5):1248-1259.
105. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gyn Onc 2006; 100(1):27-32.
106. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43(2):106-114.
107. de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003; 14(2):103-110.
108. Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004 Jun 28;2:21.
109. Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntané J, Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.J Surg Oncol. 2006 Sep 15;94(4):316-24.
110. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007 Feb;104(2):480-90.
111. Reichman TW, Cracchiolo B, Sama J, Bryan M, Harrison J, Pliner L et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 2005; 90(2):51-56.
112. Gori J, Castano R, Toziano M, Habich D, Staringer J, De Quiros DG et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15(2):233-239.
113. van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, Bokkel Huinink WW et al. Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26(7):663-668.
114. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001; 87(3):120- 126.
115. Chatzigeorgiou K, Economou S, Chrysafis G, Dimasis A, Zafiriou G, Setzis K et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol 2003; 125(10):424-429.
116. Lucas WE, Markman M, Howell SB. Intraperitoneal chemotherapy for advanced ovarian cancer. Am J Obstet Gynecol 1985; 152(4):474-478.
117. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann surg oncol , Spiliotis J, Halkia E.
118. http://www.texasoncology.com/types-of-cancer/ovarian-cancer/recurrent-ovarian-cancer
119. https://www.mskcc.org/clinical-updates/secondary-cytoreduction-second-chance-patients-ovarian
120. https://www.ncbi.nlm.nih.gov/pubmed/25391263
121. https://www.ncbi.nlm.nih.gov/pubmed/20035540